DIVI'S LABORATORIES LTD. - 532488 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Intimation of Notice of Postal Ballot as enclosed.24-02-2022
24-02-2022
Earnings Call for Q3FY22 of Divi's Laboratories
Conference Call with Divi's Laboratories Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.11-02-2022
Q3FY22 Quarterly Result Announced for Divi's Laboratories Ltd.
Pharmaceuticals company Divi's Laboratories announced Q3FY22 results: Earned a consolidated total income of Rs 2510 crores for the third quarter of the current year as against a total income of Rs 1721 crores during the corresponding quarter of last year, reflecting a growth of 46%. Profit before Tax (PBT) for the quarter grew by 61 % to Rs 1034 crores, as against a PBT of Rs 642 crores during the corresponding quarter of last year. Profit after Tax (PAT) for the current quarter grew by 92% to Rs 902 crores as against a PAT of Rs 4 71 crores for the corresponding quarter of last year For the 9-month period ended December 31, 2021, the company earned a PAT of Rs 2066 crores on a total income of Rs 6503 crores, as against a PAT of Rs 1482 crores on a total income of Rs 5224 crores during the corresponding previous period. Result PDF11-02-2022
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Change in Directorate
Outcome of Board Meeting held on 11.02.2022 - re-appointment of directors11-02-2022
DIVI'S LABORATORIES LTD. - 532488 - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2021
Further to our intimation dated February 01, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on February 11, 2022 has, inter alia approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2021. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and nine months ended December 31, 2021 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and nine months ended December 31, 2021 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 10.30 Hrs and concluded at 11.50 Hrs 111-02-2022
DIVI'S LABORATORIES LTD. - 532488 - Revised Schedule Of Earnings Conference Call Q3 FY22
Further to our intimations dated January 28, 2022 and February 01, 2022, we hereby inform that the earnings conference call for Q3FY22 has been rescheduled to February 11, 2022. Details of the revised earnings conference call is enclosed herewith. This is for your information and records.03-02-2022
DIVI'S LABORATORIES LTD. - 532488 - Update on board meeting
The Board Meeting to be held on 04/02/2022 has been revised to 11/02/2022 The Board Meeting to be held on 04/02/2022 has been revised to 11/02/202201-02-2022
DIVI'S LABORATORIES LTD. - 532488 - Schedule Of Earnings Conference Call Q3 FY22
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of earnings conference call for Q3FY22 to be held on February 04, 2022 at 14:00 hrs IST. This is for your information and records.28-01-2022
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Intimation for Inter-Alia, Considering And Approving The Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2021.
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2022 ,inter alia, to consider and approve Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Friday, February 04, 2022, inter-alia, to consider and approve the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2021. As informed earlier, pursuant to the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for dealing in securities of the Company has been closed for Designated Persons and their Immediate Relatives, as well as Insiders covered under the Code, from January 01, 2022 till 48 hours after the declaration of Unaudited Financial Results for the quarter and nine months ended December 31, 2021.25-01-2022
Divis Laboratories Q3 PAT seen up 42.7% YoY to Rs 671.7 cr: Prabhudas Lilladher
Net Sales are expected to increase by 28.4 percent Y-o-Y (up 9.9 percent Q-o-Q) to Rs 2,184 crore, according to Prabhudas Lilladher.13-01-2022